At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 81 enrolled
Drug / intervention
Debio 0932drug
Likely dose
Debio 0932 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I Dose-escalation, Pharmacokinetic and Pharmacodynamic Study of Debio 0932, a Novel Hsp90-inhibitor, Administered Orally, in Patients With Advanced Solid Tumours or Lymphoma
In Brief
A Phase 1 clinical trial evaluating Debio 0932 for Cancer and 3 related conditions. Completed, enrolled 81 participants across 3 sites.
Detailed Summary
The purpose of this study is to determine the maximum tolerated dose of Debio 0932 when administered orally, every-other-day or daily during the first 30 days, in patients with solid tumours or lymphoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer, Neoplasms, Solid Tumors, Lymphoma
CountriesFrance
Collaborators--
Timeline
Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2010
First PostedJul 2010
Primary CompletionApr 2013
TodayJul 2026
First PostedJul 23, 2010
Enrollment StartApr 1, 2010
Primary CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 15.9 years ago
Interventions
Debio 0932drug
Gelatin capsules of 2 dosage strengths (25 mg or 100 mg) The maximum dose will depend on the number of dose levels necessary to determine the MTD. In both schedules the study treatment will be continued, until one of the study treatment discontinuation criteria is met.